Skip to main content

Alliance A021804: A prospective, multi-institutional phase II trial evaluating temozolomide versus temozolomide and olaparib for advanced pheochromocytoma and paraganglioma.

Publication ,  Conference
Del Rivero, J; Perez, K; Geyer, SM; Khalil, MF; Vijendran, A; Kordaris-Corkill, A; Shergill, A; Spencer, KR; Soares, HP; Lopez, CD; Nixon, AB ...
Published in: JOURNAL OF CLINICAL ONCOLOGY
2023

Duke Scholars

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

2023

Volume

41

Issue

16

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Del Rivero, J., Perez, K., Geyer, S. M., Khalil, M. F., Vijendran, A., Kordaris-Corkill, A., … O’Reilly, E. M. (2023). Alliance A021804: A prospective, multi-institutional phase II trial evaluating temozolomide versus temozolomide and olaparib for advanced pheochromocytoma and paraganglioma. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

2023

Volume

41

Issue

16

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences